Omnicell (OMCL) Competitors

Omnicell (NASDAQ:OMCL) and Veradigm (NASDAQ:MDRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment and dividends.

Does the media prefer OMCL or MDRX?

In the previous week, Omnicell had 4 more articles in the media than Veradigm. MarketBeat recorded 6 mentions for Omnicell and 2 mentions for Veradigm. Veradigm's average media sentiment score of 0.81 beat Omnicell's score of 0.18 indicating that Veradigm is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veradigm	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer OMCL or MDRX?

Veradigm received 130 more outperform votes than Omnicell when rated by MarketBeat users. However, 66.89% of users gave Omnicell an outperform vote while only 58.51% of users gave Veradigm an outperform vote.

Company	Underperform	Outperform
Omnicell	Outperform Votes 499 66.89%	Underperform Votes 247 33.11%
Veradigm	Outperform Votes 629 58.51%	Underperform Votes 446 41.49%

Do analysts prefer OMCL or MDRX?

Omnicell currently has a consensus target price of $50.00, indicating a potential upside of 17.45%. Veradigm has a consensus target price of $12.00, indicating a potential upside of 31.87%. Given Veradigm's stronger consensus rating and higher probable upside, analysts clearly believe Veradigm is more favorable than Omnicell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Veradigm	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Is OMCL or MDRX more profitable?

Veradigm has a net margin of 0.00% compared to Omnicell's net margin of -1.66%. Omnicell's return on equity of 2.55% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	-1.66%	2.55%	1.35%
Veradigm	N/A	N/A	N/A

Which has more volatility & risk, OMCL or MDRX?

Omnicell has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Veradigm has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Which has better earnings and valuation, OMCL or MDRX?

Veradigm has lower revenue, but higher earnings than Omnicell.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.15B	1.72	-$20.37M	-$0.39	-109.15
Veradigm	N/A	N/A	N/A	N/A	N/A

Do institutionals & insiders have more ownership in OMCL or MDRX?

97.7% of Omnicell shares are owned by institutional investors. 2.6% of Omnicell shares are owned by insiders. Comparatively, 2.3% of Veradigm shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Omnicell beats Veradigm on 8 of the 13 factors compared between the two stocks.